Critical Care (Mar 2023)

Association of early mobility with the incidence of deep-vein thrombosis and mortality among critically ill patients: a post hoc analysis of PREVENT trial

  • Hasan M. Al-Dorzi,
  • Samah AlQahtani,
  • Abdulaziz Al-Dawood,
  • Fahad M. Al-Hameed,
  • Karen E. A. Burns,
  • Sangeeta Mehta,
  • Jesna Jose,
  • Sami J. Alsolamy,
  • Sheryl Ann I. Abdukahil,
  • Lara Y. Afesh,
  • Mohammed S. Alshahrani,
  • Yasser Mandourah,
  • Ghaleb A. Almekhlafi,
  • Mohammed Almaani,
  • Ali Al Bshabshe,
  • Simon Finfer,
  • Zia Arshad,
  • Imran Khalid,
  • Yatin Mehta,
  • Atul Gaur,
  • Hassan Hawa,
  • Hergen Buscher,
  • Hani Lababidi,
  • Abdulsalam Al Aithan,
  • Yaseen M. Arabi,
  • for the Saudi Critical Care Trials Group

DOI
https://doi.org/10.1186/s13054-023-04333-9
Journal volume & issue
Vol. 27, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background This study assessed the mobility levels among critically ill patients and the association of early mobility with incident proximal lower-limb deep-vein thrombosis and 90-day mortality. Methods This was a post hoc analysis of the multicenter PREVENT trial, which evaluated adjunctive intermittent pneumatic compression in critically ill patients receiving pharmacologic thromboprophylaxis with an expected ICU stay ≥ 72 h and found no effect on the primary outcome of incident proximal lower-limb deep-vein thrombosis. Mobility levels were documented daily up to day 28 in the ICU using a tool with an 8-point ordinal scale. We categorized patients according to mobility levels within the first 3 ICU days into three groups: early mobility level 4–7 (at least active standing), 1–3 (passive transfer from bed to chair or active sitting), and 0 (passive range of motion). We evaluated the association of early mobility and incident lower-limb deep-vein thrombosis and 90-day mortality by Cox proportional models adjusting for randomization and other co-variables. Results Of 1708 patients, only 85 (5.0%) had early mobility level 4–7 and 356 (20.8%) level 1–3, while 1267 (74.2%) had early mobility level 0. Patients with early mobility levels 4–7 and 1–3 had less illness severity, femoral central venous catheters, and organ support compared to patients with mobility level 0. Incident proximal lower-limb deep-vein thrombosis occurred in 1/85 (1.3%) patients in the early mobility 4–7 group, 7/348 (2.0%) patients in mobility 1–3 group, and 50/1230 (4.1%) patients in mobility 0 group. Compared with early mobility group 0, mobility groups 4–7 and 1–3 were not associated with differences in incident proximal lower-limb deep-vein thrombosis (adjusted hazard ratio [aHR] 1.19, 95% confidence interval [CI] 0.16, 8.90; p = 0.87 and 0.91, 95% CI 0.39, 2.12; p = 0.83, respectively). However, early mobility groups 4–7 and 1–3 had lower 90-day mortality (aHR 0.47, 95% CI 0.22, 1.01; p = 0.052, and 0.43, 95% CI 0.30, 0.62; p < 0.0001, respectively). Conclusions Only a small proportion of critically ill patients with an expected ICU stay ≥ 72 h were mobilized early. Early mobility was associated with reduced mortality, but not with different incidence of deep-vein thrombosis. This association does not establish causality, and randomized controlled trials are required to assess whether and to what extent this association is modifiable. Trial registration The PREVENT trial is registered at ClinicalTrials.gov, ID: NCT02040103 (registered on 3 November 2013) and Current controlled trials, ID: ISRCTN44653506 (registered on 30 October 2013).

Keywords